Lumexa Imaging (LMRI) Q3 2026: EPS Beats by 43% as Interest Costs Halve

Lumexa Imaging Holdings reported Q3 2026 adjusted EPS of $0.26, well ahead of the $0.182 consensus estimate, a 42.86% positive surprise that pushed the company to its strongest quarterly earnings performance since going public. The bottom-line beat was not driven by a revenue windfall but by a structural change in the company's cost base: interest expense fell to $15.7 million from $30.6 million a year earlier, a direct consequence of the post-IPO refinancing of its capital structure.

That halving of interest costs was enough to flip Lumexa from a net loss of $3.5 million in Q3 2025 to net income of $7.18 million in the most recent quarter. Revenue came in at $271.97 million, edging past the $269.89 million estimate by 0.77%, so the top-line beat was modest. The profit story is almost entirely a financing story, which matters for how investors should read the guidance raise that followed.

Management raised full-year adjusted EPS guidance to $0.86 to $0.90, up from a prior range of $0.71 to $0.77, attributing the improvement primarily to a lower assumed effective tax rate. Full-year revenue guidance of $1.045 billion to $1.097 billion was left untouched, and the adjusted EBITDA guidance midpoint held at $238 million, though the range was narrowed to $236 million to $240 million from $235 million to $241 million.

On the operational side, consolidated advanced procedure volume rose 7.9% to 200,600, and the mix of higher-value MRI and CT scans reached a record 31.8% of consolidated volumes. Same-center advanced volume grew 6.6% on a consolidated basis. Adjusted EBITDA expanded to $62.59 million from $59.13 million, with margin ticking up to 23.0% from 22.8%, suggesting the core imaging business is adding volume efficiently even as general and administrative expenses rose sharply to $30.0 million from $17.1 million, partly reflecting roughly $7 million in incremental public company costs in 2026.

Lumexa ended the quarter with $90.0 million in cash and equivalents and $821.5 million in long-term debt, keeping leverage elevated even after the refinancing. The company said it is actively opening three new de novo centers and remains on pace for 8 to 10 new center openings this year, with CEO Caitlin Zulla noting that newer de novo cohorts continue to ramp on plan. The pace of de novo expansion and the trajectory of G&A expenses are the two variables most worth monitoring heading into the Q4 2026 report.